Exome Sequencing of Phenotypic Extremes Identifies CAV2 and TMC6 as Interacting Modifiers of Chronic Pseudomonas aeruginosa Infection in Cystic Fibrosis

Discovery of rare or low frequency variants in exome or genome data that are associated with complex traits often will require use of very large sample sizes to achieve adequate statistical power. For a fixed sample size, sequencing of individuals sampled from the tails of a phenotype distribution (i.e., extreme phenotypes design) maximizes power and this approach was recently validated empirically with the discovery of variants in DCTN4 that influence the natural history of P. aeruginosa airway infection in persons with cystic fibrosis (CF; MIM219700). The increasing availability of large exome/genome sequence datasets that serve as proxies for population-based controls affords the opportunity to test an alternative, potentially more powerful and generalizable strategy, in which the frequency of rare variants in a single extreme phenotypic group is compared to a control group (i.e., extreme phenotype vs. control population design). As proof-of-principle, we applied this approach to search for variants associated with risk for age-of-onset of chronic P. aeruginosa airway infection among individuals with CF and identified variants in CAV2 and TMC6 that were significantly associated with group status. These results were validated using a large, prospective, longitudinal CF cohort and confirmed a significant association of a variant in CAV2 with increased age-of-onset of P. aeruginosa airway infection (hazard ratio = 0.48, 95% CI=[0.32, 0.88]) and variants in TMC6 with diminished age-of-onset of P. aeruginosa airway infection (HR = 5.4, 95% CI=[2.2, 13.5]) A strong interaction between CAV2 and TMC6 variants was observed (HR=12.1, 95% CI=[3.8, 39]) for children with the deleterious TMC6 variant and without the CAV2 protective variant. Neither gene showed a significant association using an extreme phenotypes design, and conditions for which the power of an extreme phenotype vs. control population design was greater than that for the extreme phenotypes design were explored.

[1]  Andriy Derkach,et al.  Association analysis using next-generation sequence data from publicly available control groups: the robust variance score statistic , 2014, Bioinform..

[2]  F. Accurso,et al.  Cystic fibrosis transmembrane conductance regulator and pseudomonas. , 2014, American journal of respiratory and critical care medicine.

[3]  J. Shendure,et al.  A general framework for estimating the relative pathogenicity of human genetic variants , 2014, Nature Genetics.

[4]  K. Claes,et al.  Polymorphisms in the lectin pathway genes as a possible cause of early chronic Pseudomonas aeruginosa colonization in cystic fibrosis patients. , 2012, Human immunology.

[5]  J. Emerson,et al.  Risk factors for age at initial Pseudomonas acquisition in the cystic fibrosis epic observational cohort. , 2012, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[6]  M. Rieder,et al.  Optimal unified approach for rare-variant association testing with application to small-sample case-control whole-exome sequencing studies. , 2012, American journal of human genetics.

[7]  G. Cutting,et al.  Heritability of respiratory infection with Pseudomonas aeruginosa in cystic fibrosis. , 2012, The Journal of pediatrics.

[8]  M. Rieder,et al.  Exome sequencing of extreme phenotypes identifies DCTN4 as a modifier of chronic Pseudomonas aeruginosa infection in cystic fibrosis , 2012, Nature Genetics.

[9]  L. Dupré,et al.  EVER Proteins, Key Elements of the Natural Anti-Human Papillomavirus Barrier, Are Regulated upon T-Cell Activation , 2012, PloS one.

[10]  Fred A. Wright,et al.  Genome-wide association and linkage identify modifier loci of lung disease severity in cystic fibrosis at 11p13 and 20q13.2 , 2011, Nature Genetics.

[11]  M. Drumm,et al.  Phospholipase C-β3 Is a Key Modulator of IL-8 Expression in Cystic Fibrosis Bronchial Epithelial Cells , 2011, The Journal of Immunology.

[12]  P. Paré,et al.  Modulatory effect of the SLC9A3 gene on susceptibility to infections and pulmonary function in children with cystic fibrosis , 2011, Pediatric pulmonology.

[13]  Y. Nikolsky,et al.  Interactions between an inflammatory response to infection and protein trafficking pathways favor correction of defective protein trafficking in Cystic Fibrosis , 2010, Bioinformation.

[14]  J. Clancy,et al.  Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. , 2010, The New England journal of medicine.

[15]  J. Wright,et al.  The expanding roles of caveolin proteins in microbial pathogenesis , 2009, Communicative & integrative biology.

[16]  Gonçalo R. Abecasis,et al.  The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..

[17]  Margaret Rosenfeld,et al.  Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'. , 2009, Contemporary clinical trials.

[18]  M. Gadjeva,et al.  Cystic fibrosis transmembrane conductance regulator and caveolin-1 regulate epithelial cell internalization of Pseudomonas aeruginosa. , 2009, American journal of physiology. Cell physiology.

[19]  S. Randell,et al.  Counteracting Signaling Activities in Lipid Rafts Associated with the Invasion of Lung Epithelial Cells by Pseudomonas aeruginosa* , 2009, Journal of Biological Chemistry.

[20]  D. Rotin,et al.  High-content Functional Screen to Identify Proteins that Correct F508del-CFTR Function*S , 2009, Molecular & Cellular Proteomics.

[21]  Yuri Nikolsky,et al.  MetaMiner (CF): a disease-oriented bioinformatics analysis environment. , 2009, Methods in molecular biology.

[22]  M. Favre,et al.  Role of Zn2+ Ions in Host-Virus Interactions , 2008, Journal of Virology.

[23]  M. Corey,et al.  Complex two-gene modulation of lung disease severity in children with cystic fibrosis. , 2008, The Journal of clinical investigation.

[24]  M. Ozbun,et al.  Human Papillomavirus Type 31 Uses a Caveolin 1- and Dynamin 2-Mediated Entry Pathway for Infection of Human Keratinocytes , 2007, Journal of Virology.

[25]  M. Konstan,et al.  Inflammation and anti-inflammatory therapies for cystic fibrosis. , 2007, Clinics in chest medicine.

[26]  A. Wiik,et al.  Autoantibody response to BPI predict disease severity and outcome in cystic fibrosis. , 2007, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[27]  C. Goss,et al.  CFTR genotype as a predictor of prognosis in cystic fibrosis. , 2006, Chest.

[28]  L. Dupont,et al.  Evaluating the “Leeds criteria” for Pseudomonas aeruginosa infection in a cystic fibrosis centre , 2006, European Respiratory Journal.

[29]  G. Döring,et al.  Eradication of Pseudomonas aeruginosa in cystic fibrosis patients , 2006, European Respiratory Journal.

[30]  Michael R Knowles,et al.  Genetic modifiers of lung disease in cystic fibrosis. , 2005, The New England journal of medicine.

[31]  J. Wright,et al.  Pseudomonas Invasion of Type I Pneumocytes Is Dependent on the Expression and Phosphorylation of Caveolin-2* , 2005, Journal of Biological Chemistry.

[32]  M. Kosorok,et al.  Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. , 2005, JAMA.

[33]  R. Gibson,et al.  Pathophysiology and management of pulmonary infections in cystic fibrosis. , 2003, American journal of respiratory and critical care medicine.

[34]  Gordon Johnston,et al.  Statistical Models and Methods for Lifetime Data , 2003, Technometrics.

[35]  D. Lowy,et al.  Papillomaviruses infect cells via a clathrin-dependent pathway. , 2003, Virology.

[36]  M. Denton,et al.  Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. , 2003, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[37]  J. Emerson,et al.  Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis , 2002, Pediatric pulmonology.

[38]  J. Emerson,et al.  Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis. , 2001, The Journal of infectious diseases.

[39]  Matthew R. Parsek,et al.  Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms , 2000, Nature.

[40]  L. Schwichtenberg,et al.  Mucoid Pseudomonas aeruginosa, TNF-alpha, and IL-1beta, but not IL-6, induce human beta-defensin-2 in respiratory epithelia. , 2000, American journal of respiratory cell and molecular biology.

[41]  P. J. Byard,et al.  Gender differences in cystic fibrosis: Pseudomonas aeruginosa infection. , 1995, Journal of clinical epidemiology.

[42]  C. Mellis,et al.  Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis , 1992, Pediatric pulmonology.

[43]  D. Harrington,et al.  Counting Processes and Survival Analysis , 1991 .